3 high dividend stocks to buy for sale

There are not as many more attractive combinations for investors seeking income than a high dividend yield and a low price. The bad news is that few excellent actions meet these criteria. The good news, though, is that a few do it.

AbbVie (NYSE: ABBV), AT & T (NYSE: T), and Gilead Sciences (NASDAQ: GILD) claim attractive dividend yields and very attractive valuations. Here's what you need to know about these three high-dividend stocks that you can buy for sale right now.

Source of the image: Getty Images.

1. AbbVie

The AbbVie dividend is currently 6.5%. This fantastic return is not the only thing to like from the dividend of the big drug maker. The company has increased its dividend by nearly 168% since its split from Abbott Laboratories in 2013. AbbVie remains committed to rewarding its shareholders with dividend increases.

In addition to offering a high dividend yield, the AbbVie stock is very cheap. Shares are trading at just over seven times the expected profits. This is one of the lowest ratings of the pharmaceutical industry and it is particularly appealing for a company that has generated free cash flow of over $ 9.8 billion over the past year. Last 12 months.

What is the trap? Investors worry about the decline in Humira sales and AbbVie dependence on immunology medication. There is also a lot of skepticism about the ongoing $ 63 billion acquisition of AbbVie. Allergan.

On the other hand, AbbVie recently won an extremely important Rinvoq approval by the FDA for the treatment of rheumatoid arthritis. The company won another victory earlier this year when the FDA approved Skyrizi for the treatment of psoriasis. Both drugs should be true pillars for AbbVie and, along with the current stars Imbruvica and Venclexta, help the company overcome the difficulties resulting from the fall in Humira sales.

2. AT & T

AT & T continues to be one of the top dividend paying stocks in the market with a return of more than 5.8%. The telecommunications giant may not give shareholders huge dividend increases, but it boasts an impressive history of 35 consecutive years of dividend increases.

Shares are currently trading at around 9.6x expected earnings. This level gives AT & T a more attractive value than many of its peers in the telecommunications industry.

Society is certainly facing great challenges. AT & T's television segment was relatively messy with subscribers dropping DIRECTV subscriptions and canceling their subscription to HBO after the popular Game of thrones packed series. A huge debt of nearly $ 160 billion also threatens society.

However, apart from the television industry, AT & T's business appears to be doing rather well. The company is also paying off its debt. Do not expect phenomenal growth from AT & T, but the rise of 5G broadband wireless networks is expected to boost society in the years to come. More importantly, AT & T should maintain these good dividends.

3. Gilead Sciences

Gilead Sciences has no long experience in dividend distribution – the company launched its dividend program just four years ago. But although the story of the great biotech's dividends is short, it is definitely sweet. Gilead's dividend is currently 4% and the company has increased its dividend by nearly 47% since 2015.

The stock is also a good price. Gilead shares are trading at just over nine times the expected profits. The good news for the company is that it has returned to earnings and earnings growth after a long pullback due to lower sales of its hepatitis C franchise.

Gilead has not fully emerged from the shadows of his hepatitis C problems. Biotech has encountered pipeline issues, including spontaneous blurring in advanced phase-of-stage studies of untreated steatohepatitis. alcoholic (NASH), a liver disease. Gilead could also face barriers to investment in pharmaceutical stocks, particularly the US government's threat to impose restrictions on how companies set drug prices.

Nevertheless, Gilead's future looks more promising than it has seemed for a long time. Gilead has a strong new CEO at Dan O 'Day. He could soon get the regulatory approvals for the potentially unbeatable filgotinib drug in immunology. The anti-HIV drugs of biotechnology, especially Biktarvy, continue to work very well. The Gilead dividend will likely increase in the future, as will its valuation.